Anacor Pharmaceuticals Announces Positive Results From The First Of Two Phase 3 Trials Of Tavaborole For Onychomycosis
Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive
preliminary results from the first of two Phase 3 trials of tavaborole,
its topical anti-fungal for onychomycosis, a fungal infection of the
nail and nail...